Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Galsky, Matthew; Arranz Arija, Jose; Bamias, Aristotelis; Davis, Ian; De Santis, Maria; Kikuchi, Eiji; Garcia-del-Muro, Xavier; De Giorgi, Ugo; Mencinger, Marina; Izumi, Kouji; Panni, Stefano; Gumus, Mahmut; Ozguroglu, Mustafa; Kalebasty, Arash; Park, Se; Alekseev, Boris; Schutz, Fabio; Li, Jian-Ri; Ye, Dingwei; Vogelzang, Nicholas; Bernhard, Sandrine; Tayama, Darren; Mariathasan, Sanjeev; Mecke, Almut; Thastrom, AnnChristine; Grande, Enrique

doi:10.1016/s0140-6736(20)30230-0

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Atıf İçin Kopyala

Galsky M. D. , Arranz Arija J. A. , Bamias A., Davis I. D. , De Santis M., Kikuchi E., ...Daha Fazla

LANCET, cilt.395, sa.10236, ss.1547-1557, 2020 (SCI İndekslerine Giren Dergi)

Cilt numarası: 395 Konu: 10236
Basım Tarihi: 2020
Doi Numarası: 10.1016/s0140-6736(20)30230-0
Dergi Adı: LANCET
Sayfa Sayıları: ss.1547-1557

Özet

Background Atezolizumab can induce sustained responses in metastatic urothelial carcinoma. We report the results of IMvigor130, a phase 3 trial that compared atezolizumab with or without platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in first-line metastatic urothelial carcinoma.